Current advancements and potential strategies in the development of MERS-CoV vaccines

Expert Review of Vaccines

Volumn 13, Issue 6, 2014, Pages 761-774

  Zhang, Naru ^a   Jiang, Shibo ^a,b   Du, Lanying ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

adjuvants; administration routes; coronavirus; MERS CoV; Middle East respiratory syndrome; receptor binding domain; spike protein; subunit vaccines; vaccines

Indexed keywords

DNA VACCINE; MERS COV VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; CORONAVIRUS SPIKE GLYCOPROTEIN; IMMUNOLOGICAL ADJUVANT; VIRUS VACCINE;

DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; IMMUNOGENICITY; MIDDLE EAST RESPIRATORY SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS CHARACTERIZATION; ANIMAL; CORONAVIRUS INFECTIONS; DISEASE MODEL; DRUG DEVELOPMENT; EPIDEMIOLOGY; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE EAST; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PROCEDURES; TRENDS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; MIDDLE EAST; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINATION; VACCINES, SUBUNIT; VIRAL VACCINES;

EID: 84901003129     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.912134     Document Type: Review

References (128)

1. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814-20
2. WHO. Middle East respiratory syndrome coronavirus. (MERS-CoV)-update. Available from: www.who.int/csr/don/2014-03-26/en/[Last accessed 26 March 2014]
3. Memish ZA, Mishra N, Olival K, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013;19(11):1819-23
4. Haagmans BL, Al Dhahiry SH, Reusken CB, et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 2013;14(2):140-5
5. Reusken CB, Haagmans BL, Müller MA, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013;13(10): 859-66
6. Balkhair A, Al Maamari K, Alawi FB. The struggle against MERS-CoV (the novel coronavirus). Oman Med J 2013;28(4): 226-7
7. Memish ZA, Zumla AI, Al-Hakeem RF, et al. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013;368:2487-94
8. Mailles A, Blanckaert K, Chaud P, et al. First cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveill 2013;18(24):pii. 20502
9. Guery B, Poissy J, el Mansouf L, et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet 2013; 381 (9885):2265-72
10. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature 2004;430(6996): 242-9
11. McBride R, Fielding BC. The role of Severe Acute Respiratory Syndrome (SARS)-coronavirus accessory proteins in virus pathogenesis. Viruses 2012;4(11):2902-23
12. Muller MA, Raj VS, Muth D, et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 2012;3:6
13. Woo PC, Lau SK, Lam CS, et al. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol 2012;86(7): 3995-4008
14. Fouchier RA, Hartwig NG, Bestebroer TM, et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci USA 2004; 101(16):6212-16
15. Lau SK, Woo PC, Yip CC, et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol 2006;44(6):2063-71
16. Woo PC, Lau SK, Chu CM, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005;79(2):884-95
17. Zhong N, Zheng B, Li Y, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 2003;362(9393): 1353-8
18. Chan JF, Lau SK, Woo PC. The emerging novel Middle East respiratory syndrome coronavirus: the "knowns" and "unknowns". J Formos Med Assoc 2013;112(7):372-81
19. Woo PC, Lau SK, Li KS, et al. Molecular diversity of coronaviruses in bats. Virology 2006;351(1):180-7
20. Woo PC, Wang M, Lau SK, et al. Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. J Virol 2007;81(4): 1574-85
21. Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 2005;102(39): 14040-5
22. Niemeyer D, Zillinger T, Muth D, et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol 2013;87(22): 12489-95
23. Scobey T, Yount BL, Sims AC, et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci USA 2013;110(40):16157-62
24. Hurst KR, Ye R, Goebel SJ, et al. An interaction between the nucleocapsid protein and a component of the replicase-transcriptase complex is crucial for the infectivity of coronavirus genomic RNA. J Virol 2010;84(19):10276-88
25. Xu Y, Lou Z, Liu Y, et al. Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J Biol Chem 2004;279(47):49414- 19
26. Bonavia A, Zelus BD, Wentworth DE, et al. Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E. J Virol 2003; 77(4):2530-8
27. Taguchi F. The S2 subunit of the murine coronavirus spike protein is not involved in receptor binding. J Virol 1995;69(11): 7260-3
28. Wu K, Li W, Peng G, Li F. Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor. Proc Natl Acad Sci USA 2009;106(47):19970-4
29. Peng G, Sun D, Rajashankar KR, et al. Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. Proc Natl Acad Sci USA 2011;108(26):10696-701
30. Zhu X, Liu Q, Du L, et al. Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis 2013;5(Suppl 2):S142
31. Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005;309(5742): 1864-8
32. Wang N, Shi X, Jiang L, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013;23(8):986-93
33. Hofmann H, Pyrc K, van der Hoek L, et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci USA 2005;102(22):7988-93
34. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426(6965):450-4
35. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013;495(7440):251-4
36. Chen Y, Rajashankar KR, Yang Y, et al. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J Virol 2013;87(19):10777-83
37. Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013;500(7461):227-31
38. Gao J, Lu G, Qi J, et al. Structure of the fusion core and inhibition of fusion by a heptad-repeat peptide derived from the S protein of MERS-CoV. J Virol 2013; 87(24):13134-40
39. Lu L, Liu Q, Zhu Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus (MERS-CoV) fusion inhibitor. Nat Commun 2014;5:3067
40. Pak JE, Sharon C, Satkunarajah M, et al. Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain. J Mol Biol 2009;388(4):815-23
41. Prabakaran P, Gan J, Feng Y, et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 2006;281(23): 15829-36
42. Hwang WC, Lin Y, Santelli E, et al. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody. J Biol Chem 2006;281(45):34610-16
43. Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nature Rev Microbiol 2009;7(3):226-36
44. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nature Rev Microbiol 2013;11(12):836-48
45. Jiang S, Bottazzi ME, Du L, et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines 2012; 11(12):1405-13
46. Zakhartchouk AN, Sharon C, Satkunarajah M, et al. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine 2007;25(1):136-43
47. Almazán F, DeDiego ML, Sola I, et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBio 2013;4(5): e00650-13
48. Cao Z, Liu L, Du L, et al. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J 2010;7(1):299
49. Du L, Zhao G, Chan C, et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 2009;393(1): 144-50
50. Du L, Zhao G, He Y, et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 2007;25(15):2832-8
51. He Y, Lu H, Siddiqui P, et al. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005;174(8):4908-15
52. Song F, Fux R, Provacia LB, et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 2013;87(21):11950-4
53. Czub M, Weingartl H, Czub S, et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 2005;23(17):2273-9
54. Olsen CW. A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination. Vet Microbiol 1993;36(1):1-37
55. Mou H, Raj VS, van Kuppeveld FJ, et al. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013;87(16): 9379-83
56. Du L, Zhao G, Kou Z, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013;87(17):9939-42
57. Du L, Kou Z, Ma C, et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 2013;8(12):e81587
58. Yang Y, Zhang L, Geng H, et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 2013;4(12):951-61
59. Zhou J, Wang W, Zhong Q, et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 2005;23(24):3202-9
60. Kong WP, Xu L, Stadler K, et al. Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization. J Virol 2005;79(22): 13915-23
61. Lamirande EW, DeDiego ML, Roberts A, et al. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol 2008;82(15): 7721-4
62. See RH, Zakhartchouk AN, Petric M, et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 2006;87(3): 641-50
63. Graham RL, Becker MM, Eckerle LD, et al. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med 2012;18(12):1820-6
64. Qu D, Zheng B, Yao X, et al. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine 2005;23(7):924-31
65. Netland J, DeDiego ML, Zhao J, et al. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology 2010;399(1): 120-8
66. Fett C, DeDiego ML, Regla-Nava JA, et al. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J Virol 2013;87(12): 6551-9
67. Kim JH, Jacob J. DNA vaccines against influenza viruses. Curr Top Microbiol Immunol 2009;333:197-210
68. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006;58(1):32-45
69. Satkauskas S, Bureau MF, Mahfoudi A, Mir LM. Slow accumulation of plasmid in muscle cells: supporting evidence for a mechanism of DNA uptake by receptor-mediated endocytosis. Mol Ther 2001;4(4):317-23
70. Shamlou PA. Scaleable processes for the manufacture of therapeutic quantities of plasmid DNA. Biotechnol Appl Biochem 2003;37(3):207-18
71. Prather KJ, Sagar S, Murphy J, Chartrain M. Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification. Enzyme Microb Technol 2003; 33(7):865-83
72. Hoare M, Levy MS, Bracewell DG, et al. Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic. Biotechnol Prog 2005;21(6): 1577-92
73. Yang ZY, Kong WP, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004;428(6982):561-4
74. Zhao B, Jin NY, Wang RL, et al. Immunization of mice with a DNA vaccine based on severe acute respiratory syndrome coronavirus spike protein fragment 1. Viral Immunol 2006;19(3):518-24
75. Shi SQ, Peng JP, Li YC, et al. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Mol Immunol 2006; 43(11):1791-8
76. Roberts A, Lamirande EW, Vogel L, et al. Animal models and vaccines for SARS-CoV infection. Virus Res 2008;133(1):20-32
77. Woo PC, Lau SK, Tsoi HW, et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine 2005;23(42): 4959-68
78. Bisht H, Roberts A, Vogel L, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 2004;101(17): 6641-6
79. Bukreyev A, Lamirande EW, Buchholz UJ, et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004;363(9427):2122-7
80. Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003;362(9399):1895-6
81. Du L, Zhao G, Lin Y, et al. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol 2008; 180(2):948-56
82. Du L, Zhao G, Lin Y, et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine 2008; 26(13):1644-51
83. Pichla-Gollon SL, Lin S-W, Hensley SE, et al. Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J Virol 2009;83(11):5567-73
84. Gao G, Wang Q, Dai Z, et al. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes. Hum Gene Ther 2008;19(9): 927-36
85. Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 2004;78(22):12672-6
86. Lu X, Chen Y, Bai B, et al. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. Immunology 2007;122(4): 496-502
87. Liu YV, Massare MJ, Barnard DL, et al. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine 2011; 29(38):6606-13
88. Lokugamage KG, Yoshikawa-Iwata N, Ito N, et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine 2008;26(6):797-808
89. Ho Y, Lin PH, Liu CY, et al. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem Biophys Res Commun 2004;318(4):833-8
90. Sailaja G, Skountzou I, Quan FS, et al. Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology 2007;362(2):331-41
91. Wang BZ, Quan FS, Kang SM, et al. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008;82(23):11813-23
92. He Y, Zhou Y, Wu H, et al. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 2004;173(6):4050-7
93. Ma C, Li Y, Wang L, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 2014;32(18):2100-8
94. Agnihothram S, Gopal R, Yount BL, et al. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis 2014;209(7): 995-1006
95. Naz RK, Dabir P. Peptide vaccines against cancer, infectious diseases, and conception. Front Biosci 2006;12:1833-44
96. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009;30(1): 23-32
97. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 2003; 8(20):934-43
98. Lambert SL, Yang CF, Liu Z, et al. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant glucopyranosyl Lipid A. PLoS One 2012;7(12):e51618
99. Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003;2(2):197-204
100. Radosević K, Rodriguez A, Mintardjo R, et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine 2008;26(29): 3640-6
101. Baldwin SL, Bertholet S, Reese VA, et al. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol 2012;188(5):2189-97
102. Filipazzi P, Pilla L, Mariani L, et al. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res 2012;18(23): 6485-96
103. Mavroudis D, Bolonakis I, Cornet S, et al. A phase I study of the optimized cryptic peptide TERT572Y in patients with advanced malignancies. Oncology 2006; 70(4):306-14
104. Du L, Zhao G, Sun S, et al. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PLoS One 2013;8(1):e53568
105. Budimir N, Haan A, Meijerhof T, et al. Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration. Influenza Other Respir Viruses 2013;7(6):1202-9
106. Frenck RW Jr, Belshe R, Brady RC, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011;29(34): 5666-74
107. Rahman F, Dahmen A, Herzog-Hauff S, et al. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000;31(2):521-7
108. Mooney AJ, Li Z, Gabbard JD, et al. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice. J Virol 2013;87(1):363-71
109. Siu Y, Teoh K, Lo J, et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol 2008;82(22):11318-30
110. Kitabatake M, Inoue S, Yasui F, et al. SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus. Vaccine 2007;25(4):630-7
111. Takasuka N, Fujii H, Takahashi Y, et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol 2004;16(10):1423-30
112. Du L, Zhao G, Li L, et al. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun 2009;384(4):486-90
113. Khosrow Tayebati S, Ejike Nwankwo I, Amenta F. Intranasal drug delivery to the central nervous system: present status and future outlook. Curr Pharm Des 2013; 19(3):510-26
114. CDC. Seasonal Influenza (Flu). Available from: www.cdc.gov/flu/protect/ whoshouldvax.htm [Last accessed on 24 March 2014]
115. Liew FY, Russell SM, Appleyard G, et al. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol 1984;14(4):350-6
116. Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003;362(9380):263-70
117. Martina BE, Haagmans BL, Kuiken T, et al. Virology: SARS virus infection of cats and ferrets. Nature 2003;425(6961):915-15
118. Roberts A, Vogel L, Guarner J, et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol 2005;79(1):503-11
119. de Wit E, Prescott J, Baseler L, et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS One 2013;8(7): e69127
120. Yao Y, Bao L, Deng W, et al. An animal model of MERS produced by infection of Rhesus macaques with MERS coronavirus. J Infect Dis 2014;209(2):236-42
121. Coleman CM, Matthews KL, Goicochea L, Frieman MB. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol 2014;95(Pt 2): 408-12
122. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-[alpha] 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013;19(10):1313-17
123. Munster VJ, de Wit E, Feldmann H. Pneumonia from human coronavirus in a macaque model. N Engl J Med 2013; 368(16):1560-2
124. de Wit E, Rasmussen AL, Falzarano D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci USA 2013; 110(41):16598-603
125. Devitt E. Lack of small animal model hinders MERS coronavirus research. Nat Med 2013;19(8):952-2
126. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014;111(13): 4970-5
127. Reardon S. Nature news. Available from: www.nature.com/news/biologists- make-first-mouse-model-for-mers-1.14634 [Last accessed on 22 March 2014]
128. Narayanan K, Maeda A, Maeda J, Makino S. Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells. J Virol 2000; 74(17):8127-34